CAS Number312-93-6
SynonymsHexadrol phosphate; dexamethasone-21-phosphate; Dexamethasone 21-orthophosphate; Betnelan phosphate; Dexamethasone-21-dihydrogen-phosphate; Wymesone; Neodecadron; Oradexon phosphate; Dexamethasone phosphate
Molecular FormulaC22H30FO8P
Molecular Weight472.44
Density1.45g/cm3
Boiling Point669.6ºC at 760mmHg
Melting Point154-157°C (lit.)
Appearancepowder
EINECS206-232-0
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 312-93-6 |
| Catalog No. | 2A-3177055 |
| Chinese Name | 地塞米松 21-磷酸 |
| Synonyms | Hexadrol phosphate; dexamethasone-21-phosphate; Dexamethasone 21-orthophosphate; Betnelan phosphate; Dexamethasone-21-dihydrogen-phosphate; Wymesone; Neodecadron; Oradexon phosphate; Dexamethasone phosphate |
| Molecular Formula | C22H30FO8P |
| Molecular Weight | 472.44 |
| Density | 1.45g/cm3 |
| Boiling Point | 669.6ºC at 760mmHg |
| Melting Point | 154-157°C (lit.) |
| Appearance | powder |
| Storage Condition | Ventilated and low temperature drying |
| Application | Dexamethasone phosphate (Dexamethasone 21-phosphate) is a biologically inactive compound that is dephosphorylated by intraerythrocyte enzymes. The active metabolite dexamethasone is then released into |
| EINECS | 206-232-0 |
| HTC | 2937290090 |
| SMILES | CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)(O)O |
| InChI | InChI=1S/C22H30FO8P/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)21(15,23)17(25)10-20(16,3)22(12,27)18(26)11-31-32(28,29)30/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30)/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 |
| InChI Key | VQODGRNSFPNSQE-CXSFZGCWSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| MSDS | msds/177598_1_312_93_6.pdf |
| Use of | Dexamethasone phosphate (Dexamethasone 21-phosphate) is a biologically inactive compound which undergoes dephosphorylation by intra-erythrocyte enzymes. The active metabolite, dexamethasone, is then released into the circulation by simple passive diffusion through cell membranes. Dexamethasone phosphate-encapsulated erythrocyte has the potential for steroid-dependent ulcerative colitis research[1]. Properties Name dexamethasone phosphate Synonym More Synonyms Dexamethasone Phosphate Biological Activity Description Dexamethasone phosphate (Dexamethasone 21-phosphate) is a biologically inactive compound which undergoes dephosphorylation by intra-erythrocyte enzymes. The active metabolite, dexamethasone, is then released into the circulation by simple passive diffusion through cell membranes. Dexamethasone phosphate-encapsulated erythrocyte has the potential for steroid-dependent ulcerative colitis research[1]. Related Catalog Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor References [1]. Fabrizio Bossa, et al. Erythrocytes-mediated delivery of dexamethasone 21-phosphate in steroid-dependent ulcerative colitis: a randomized, double-blind Sham-controlled study. Inflamm Bowel Dis. 2013 Aug;19(9):1872-9. Chemical & Physical Properties Molecular Formula C22H30FO8P Exact Mass 472.16600 PSA 151.17000 LogP 2.01270 Index of Refraction 1.594 InChIKey VQODGRNSFPNSQE-CXSFZGCWSA-N Toxicological Information CHEMICAL IDENTIFICATION RTECS NUMBER : CHEMICAL NAME : Pregna-1,4-diene-3,20-dione, 9-fluoro-11-beta,17,21-trihydroxy-16-alpha-methyl-, 21-(dihydrogen phosphate) CAS REGISTRY NUMBER : LAST UPDATED : DATA ITEMS CITED : MOLECULAR FORMULA : C22-H30-F-O8-P MOLECULAR WEIGHT : WISWESSER LINE NOTATION : L E5 B666 OV AHTTT&J A1 BF CQ E1 FV1OPQQO FQ G1 HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : TOXIC EFFECTS : Endocrine - changes in thymus weight Immunological Including Allergic - decrease in cellular immune response Immunological Including Allergic - decrease in humoral immune response TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : SEX/DURATION : female 21-22 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - endocrine system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SEX/DURATION : female 19-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - respiratory system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Intraperitoneal SEX/DURATION : female 19-20 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - hepatobiliary system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SEX/DURATION : female 8-13 day(s) after conception TOXIC EFFECTS : Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SEX/DURATION : female 1 day(s) pre-mating TOXIC EFFECTS : Reproductive - Maternal Effects - menstrual cycle changes or disorders Reproductive - Fertility - other measures of fertility TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SEX/DURATION : female 17-19 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - respiratory system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous SEX/DURATION : female 17-19 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SEX/DURATION : female 11-14 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - body wall Reproductive - Specific Developmental Abnormalities - cardiovascular (circulatory) system TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SEX/DURATION : female 14-17 day(s) after conception TOXIC EFFECTS : Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Parenteral SEX/DURATION : female 22-25 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) MUTATION DATA TEST SYSTEM : Rodent - rat DOSE/DURATION : REFERENCE : JOENAK Journal of Endocrinology. (Biochemical Soc. Book Depot, POB 32, Commerce Way, Colchester, Essex CO2 8HP, UK) V.1- 1939- Volume(issue)/page/year: 62,527,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3850 No. of Facilities: 130 (estimated) No. of Industries: 3 No. of Occupations: 10 No. of Employees: 5388 (estimated) No. of Female Employees: 2968 (estimated) Safety Information Hazard Codes Xn Risk Phrases 62 HS Code 2937290090 Synthetic Route Total: 1 Page Dexamethasone CAS#:50-02-2 Dexamethasone P... CAS#:312-93-6 Literature: Chemical and Pharmaceutical Bulletin, , vol. 22, # 7 p. 1439 - 1450 Precursor & DownStream Precursor 1 CAS#:50-02-2 Dexamethasone DownStream 0 |
| Transport Info | Product Name: DEXAMETHASONE SODIUM PHOSPHATE |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Cefazolin Related Compund D (Cefazolin Openring Lactone) | 2A-3176995 | 2A-3176995 |
| Cephalosporin Lactone Impurity | 184696-69-3 | 2A-3177031 |
| Deoxy Donepezil Hydrochloride | 1034439-57-0 | 2A-3177039 |
| Donepezil N-Oxide | 120013-84-5 | 2A-3177040 |
| DEXAMETHASONE ISONICOTINATE | 2265-64-7 | 2A-3177052 |
| Furanylfentanyl | 101345-66-8 | 2A-4177118 |
| 20 beta-hydroxymethylprednisolone | 387-66-6 | 2A-3177128 |
| 20 beta-hydroxy-6-alpha-methylprednisone | 2A-3177129 | 2A-3177129 |
| 3-Hydroxy Abacavir | 2A-3177130 | 2A-3177130 |
| Abacavir enantiomer | 136470-79-6 | 2A-3177131 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS